Video

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

Author(s):

Sara A. Hurvitz, MDAditya Bardia, MD, MPH

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

Data from the following clinical trials are discussed:

  • P1-18-16: First-line aromatase inhibitor + palbociclib with randomized switch to fulvestrant [Faslodex] + palbociclib upon detection of circulating ESR1 mutation in HR+/HER2 metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase 3 trial
  • PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2 advanced breast cancer across the MONALEESA studies
  • PD13-03: Ribociclib [Kisqali], everolimus, exemestane [Aromasin] triplet therapy in HR+/HER2 advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1
  • PD02-04: Molecular plasticity of luminal A breast cancer and response to CDK4/6 inhibition: The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib
Related Videos
Seth Wander, MD, PhD
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Cynthia X. Ma, MD, PhD
Ann H. Partridge, MD, MPH
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Bora Lim, MD, MD Anderson
Related Content
Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California, as well as a health sciences clinical professor at the University of California, Los Angeles
October 8th 2024

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Giuseppe Del Priore, MD, MPH, chief medical officer, BriaCell
October 2nd 2024

Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis